DK0931063T5 - N-substitueret indol-3-glyoxylamid med antiastmatisk, antiallergisk og immunhæmmende/immunmodulerende virkning - Google Patents

N-substitueret indol-3-glyoxylamid med antiastmatisk, antiallergisk og immunhæmmende/immunmodulerende virkning

Info

Publication number
DK0931063T5
DK0931063T5 DK97937586T DK97937586T DK0931063T5 DK 0931063 T5 DK0931063 T5 DK 0931063T5 DK 97937586 T DK97937586 T DK 97937586T DK 97937586 T DK97937586 T DK 97937586T DK 0931063 T5 DK0931063 T5 DK 0931063T5
Authority
DK
Denmark
Prior art keywords
glyoxylamide
antiasthmatic
antiallergic
immunosuppressive
substituted indole
Prior art date
Application number
DK97937586T
Other languages
Danish (da)
English (en)
Other versions
DK0931063T3 (da
Inventor
Guillaume Lebaut
Cecilia Menciu
Bernhard Kutscher
Peter Emig
Stefan Szelenyi
Kay Brune
Original Assignee
Ziopharm Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziopharm Oncology Inc filed Critical Ziopharm Oncology Inc
Application granted granted Critical
Publication of DK0931063T3 publication Critical patent/DK0931063T3/da
Publication of DK0931063T5 publication Critical patent/DK0931063T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DK97937586T 1996-09-06 1997-08-16 N-substitueret indol-3-glyoxylamid med antiastmatisk, antiallergisk og immunhæmmende/immunmodulerende virkning DK0931063T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636150A DE19636150A1 (de) 1996-09-06 1996-09-06 N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
PCT/EP1997/004474 WO1998009946A1 (fr) 1996-09-06 1997-08-16 Indol-3-glyoxylamides substitues en n aux proprietes antiasthmatiques, antiallergiques et immunosuppresseurs/immunomodulatrices

Publications (2)

Publication Number Publication Date
DK0931063T3 DK0931063T3 (da) 2007-02-19
DK0931063T5 true DK0931063T5 (da) 2010-01-11

Family

ID=7804772

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97937586T DK0931063T5 (da) 1996-09-06 1997-08-16 N-substitueret indol-3-glyoxylamid med antiastmatisk, antiallergisk og immunhæmmende/immunmodulerende virkning

Country Status (27)

Country Link
US (4) US6008231A (fr)
EP (1) EP0931063B3 (fr)
JP (1) JP3296437B2 (fr)
KR (1) KR100516321B1 (fr)
CN (3) CN100376554C (fr)
AR (1) AR008630A1 (fr)
AT (1) ATE342889T1 (fr)
AU (1) AU726521B2 (fr)
BR (1) BR9712808B1 (fr)
CA (1) CA2215013C (fr)
CZ (1) CZ302301B6 (fr)
DE (2) DE19636150A1 (fr)
DK (1) DK0931063T5 (fr)
ES (1) ES2276433T7 (fr)
HK (3) HK1021641A1 (fr)
HU (1) HU227797B1 (fr)
IL (1) IL127798A (fr)
NO (2) NO314725B3 (fr)
NZ (1) NZ334476A (fr)
PT (1) PT931063E (fr)
RU (1) RU2237661C2 (fr)
SK (1) SK285618B6 (fr)
TR (1) TR199900469T2 (fr)
TW (1) TW550256B (fr)
UA (1) UA60312C2 (fr)
WO (1) WO1998009946A1 (fr)
ZA (1) ZA977475B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
MXPA02003122A (es) * 1998-03-31 2004-04-21 Inst For Pharm Discovery Inc Acidos indolalcanoicos substituidos.
DE19814838C2 (de) * 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CZ302588B6 (cs) * 1998-04-02 2011-07-27 Ziopharm Oncology, Inc. Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19917504A1 (de) * 1999-04-17 2000-10-19 Dresden Arzneimittel Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
JP3842043B2 (ja) 1998-04-28 2006-11-08 エルビオン アクチエンゲゼルシャフト 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法
DE60043318D1 (de) 1999-08-21 2010-01-14 Nycomed Gmbh Synergistische kombination von pumafentrine und salmeterol
TWI269654B (en) * 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
DE10037310A1 (de) 2000-07-28 2002-02-07 Asta Medica Ag Neue Indolderivate und deren Verwendung als Arzneimittel
WO2003022280A2 (fr) * 2001-09-13 2003-03-20 Synta Pharmaceuticals Corp. 3-glyoxlylamide-indoles pour traitement du cancer
US6903104B2 (en) * 2001-12-06 2005-06-07 National Health Research Institutes Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
AU2003256926A1 (en) * 2002-07-26 2004-02-16 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications
RU2315046C2 (ru) * 2002-08-01 2008-01-20 Элбион Аг Способ получения гидроксииндолилглиоксиламидов высокой чистоты
DE10253426B4 (de) * 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10318609A1 (de) * 2003-04-24 2004-11-11 Elbion Ag 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
DE10318611A1 (de) 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
MX2007005434A (es) * 2004-11-08 2007-07-10 Baxter Int Composiciones de nanoparticulado de inhibidor de tubulina.
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
JP2006247963A (ja) * 2005-03-09 2006-09-21 Oji Paper Co Ltd インクジェット記録用シート
WO2006099256A2 (fr) * 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
RU2372490C2 (ru) 2005-04-29 2009-11-10 ТЕНДИКС ДИВЕЛОПМЕНТ, ЭлЭлСи Двигатель (варианты)
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
PL2363130T3 (pl) 2006-07-05 2014-09-30 Astrazeneca Ab Kombinacja inhibitorów reduktazy HMG-CoA atorwastatyny i symwastatyny z inhibitorem fosfodiesterazy, takim jak roflumilast do leczenia zapalnych chorób płuc
JP5406716B2 (ja) 2006-08-07 2014-02-05 アイアンウッド ファーマシューティカルズ インコーポレイテッド インドール化合物
WO2008073623A2 (fr) * 2006-11-02 2008-06-19 Arete Therapeutics, Inc. Inhibiteurs d'hydrolase epoxyde soluble
EP2091532A1 (fr) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Utilisation de dérivés d'acide indolyl-3-glyoxylique comprenant de l'indibuline, seuls ou combinés à d'autres agents, pour traiter le cancer
EP3563842A1 (fr) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
EP3165224A1 (fr) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Utilisation d'inhibiteurs de pde4 pour la prophylaxie et/ou la thérapie de la dyslipoproteinémie et des troubles apparentés
WO2017089347A1 (fr) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
CN109000634B (zh) * 2018-06-04 2022-06-03 上海智蕙林医疗科技有限公司 一种导航对象行进路线的提醒方法和系统

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797258A (en) * 1955-04-11 1958-06-25 Upjohn Co 3-substituted indoles
GB944443A (fr) * 1959-09-25 1900-01-01
GB1028812A (en) * 1962-08-28 1966-05-11 Ici Ltd Indole derivatives
GB1089071A (en) * 1964-02-28 1967-11-01 Merck & Co Inc Indole derivatives
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
ES2179088T3 (es) * 1994-04-01 2003-01-16 Lilly Co Eli Inhibidores de flsa2 1h-indol-3-glioxilamida.
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
DE19946301A1 (de) * 1998-04-02 2001-04-19 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
US7205299B2 (en) * 2003-06-05 2007-04-17 Zentaris Gmbh Indole derivatives having an apoptosis-inducing effect

Also Published As

Publication number Publication date
IL127798A0 (en) 1999-10-28
EP0931063A1 (fr) 1999-07-28
RU2237661C2 (ru) 2004-10-10
SK27199A3 (en) 1999-08-06
US6344467B1 (en) 2002-02-05
AU4015897A (en) 1998-03-26
HU227797B1 (en) 2012-03-28
NO991071D0 (no) 1999-03-04
CN100488948C (zh) 2009-05-20
NO991071L (no) 1999-03-04
KR100516321B1 (ko) 2005-09-23
DE19636150A1 (de) 1998-03-12
NO20030481D0 (no) 2003-01-30
JP3296437B2 (ja) 2002-07-02
ES2276433T7 (es) 2009-11-05
NZ334476A (en) 2000-05-26
SK285618B6 (sk) 2007-05-03
HK1021641A1 (en) 2000-06-23
NO314725B1 (no) 2003-05-12
JP2000505098A (ja) 2000-04-25
BR9712808A (pt) 1999-11-23
IL127798A (en) 2003-07-31
CN101219985A (zh) 2008-07-16
TR199900469T2 (xx) 1999-05-21
CA2215013C (fr) 2002-03-05
BR9712808B1 (pt) 2009-05-05
HUP9903741A2 (hu) 2000-04-28
ZA977475B (en) 1998-02-19
DK0931063T3 (da) 2007-02-19
EP0931063B1 (fr) 2006-10-18
ATE342889T1 (de) 2006-11-15
CA2215013A1 (fr) 1998-03-06
UA60312C2 (uk) 2003-10-15
WO1998009946A1 (fr) 1998-03-12
CN1227542A (zh) 1999-09-01
HK1123280A1 (en) 2009-06-12
CZ61699A3 (cs) 1999-06-16
CN100376554C (zh) 2008-03-26
US6919344B2 (en) 2005-07-19
DE59712752D1 (de) 2006-11-30
AU726521B2 (en) 2000-11-09
EP0931063B3 (fr) 2009-04-08
US20030207892A1 (en) 2003-11-06
US6008231A (en) 1999-12-28
NO20030481L (no) 1999-03-04
HK1064379A1 (en) 2005-01-28
KR20000068495A (ko) 2000-11-25
AU726521C (en) 1998-03-26
NO314725B3 (no) 2009-03-09
AR008630A1 (es) 2000-02-09
PT931063E (pt) 2007-02-28
US20020161025A1 (en) 2002-10-31
CN1496980A (zh) 2004-05-19
HUP9903741A3 (en) 2001-01-29
CN101219985B (zh) 2011-04-27
CZ302301B6 (cs) 2011-02-09
TW550256B (en) 2003-09-01
ES2276433T3 (es) 2007-06-16

Similar Documents

Publication Publication Date Title
DK0931063T3 (da) N-substitueret indol-3-glyoxylamid med antiastmatisk, antiallergisk og immunhæmmende/immunmodulerende virkning
IL121298A (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their uses
DE69532501D1 (de) Verbessertes, langwirkendes gastrointestinales und ösophagisches schutzmittel
DE59711118D1 (de) Spickeln, Zunehmen und Mindern
DE69734126D1 (de) Druckverfahren und Gerät
DE69729947D1 (de) N-substituierte 2-cyanopyrrolidine
DE19581855T1 (de) Schlagvorrichtung und Schlagverfahren
DE69932265D1 (de) Musikaktionsspielsystem und computerlesbare Aufzeichnungsvorrichtung
NO984354D0 (no) Avisingsmiddel og anvendelse av dette
HK1062827A1 (en) Cyclic amine derivatives and their use as drugs
IL121299A0 (en) 4-hydroxy-piperidine derivatives and their uses
DE69722329D1 (de) Postkarte und Umschlag
DE69724852D1 (de) Tintenstrahldruckgerät und Druckverfahren
NO964541L (no) Porphacyanin og CNC-utvidete porphyriner
DE69713817D1 (de) Schutzabdeckung und damit ausgestatteter Apparat
DE69727047D1 (de) Entpaketierer und rahmenausgleicher damit
NO985806L (no) Kitinasematerialer og fremgangsmÕter
DE69718239D1 (de) Druckvorrichtung und Druckkopf
DE69722739D1 (de) Tintenstrahldruckvorrichtung und Tintenstrahldruckverfahren
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
DK1042286T3 (da) Gamme-glutamyl- og beta-aspartyl-holdige immunmodulerende forbindelser og tilhørense fremgangsmåder
ZA981850B (en) (R) N-(1-Cyclopropylmethylpyrrolidin-2-ylmethyl)-benz-amide and its use as an antidiarrhoeal
NO991123D0 (no) 25-metylen- og 24,25-epoksy-marcfortiner og paraherkamider
IT242303Y1 (it) Attrezzo ginnico e ludico gonfiabile e sgonfiabile
KR970050818U (ko) 진흙 방석과 요